6 best EDC platforms for musculoskeletal and orthopedic trials in 2026

A knee implant trial doesn't end at database lock. It runs for years afterward, chasing patient-reported outcome scores at the 1-year, 3-year, and 5-year marks long after the surgical team has moved on. Musculoskeletal and orthopedic trials also carry device accountability requirements and post-market surveillance obligations that a platform built for pharma dosing schedules handles poorly. Viedoc's EDC software is built for that kind of adaptability, with a no-code Designer, an average 10-week study build, and a native post-market surveillance module for teams working toward Japan's PMDA requirements. This comparison reviews six EDC platforms across study design flexibility, long-term follow-up, regulatory pathway support, and lean-team usability.

If you're running device trials, you're likely managing this with a lean team, often one or two people covering data management, site training, and regulatory documentation across several studies at once. If you're a growth-stage sponsor running an inflammatory or degenerative musculoskeletal trial, you're weighing a similar trade-off between a platform that scales with your pipeline and one that overbuilds for where you are today. Either way, you need a system that doesn't put a full-time programmer between your protocol changes and your live database.

Enterprise EDC platforms sized for large pharma programs bring vendor-side programming overhead a lean team can't absorb, and their pricing rarely flexes around device accountability fields or multi-year outcome follow-up. Commodity tools, meanwhile, tend to lack native support for procedural visit types or post-market surveillance. The platforms below are judged on whether they meet those specific demands.

Best EDC solutions for musculoskeletal and orthopedic trials: quick comparison

These six eClinical platforms represent the most evaluated options for musculoskeletal and orthopedic trials, reviewed across study design flexibility, long-term follow-up, regulatory pathway support, and lean-team usability.

1. Viedoc

Viedoc's EDC software gives your team direct control over study design through a no-code Designer, so device-specific fields like implant serial numbers, procedural visit types, and malfunction reporting get built in-house rather than queued behind a vendor programmer. Study builds typically complete in an average of 10 weeks, with self-service setups live in as little as a day for less complex protocols. That flexibility matters most when a device study's data model doesn't fit a template built around drug dosing.

For orthopedic and MedTech teams, the standout differentiator is Viedoc's native post-market surveillance software, built for Japan's PMDA requirements and uncommon among platforms sized for lean device teams. Sonex Health, a medical device company running post-market studies of a minimally invasive carpal tunnel release technique, used Viedoc's ePRO platform to drive 98% participant visit compliance across three studies and 1,300-plus participants, without adding headcount to chase patients manually. For growth-stage sponsors running musculoskeletal trials, the same Designer scales as the portfolio grows from Phase I into Phase II.

On compliance, Viedoc supports FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and Japan's APPI, and is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure with 99.99% uptime. The Viedoc Inspection Readiness Packet gives QA teams pre-built validation documentation ahead of an inspection, and support runs 24/7, with the platform rated 4.5 out of 5 on G2 across 230-plus reviews.

"It offers customizable study workflow and tailoring it according to trial specification is easy," notes Sanchita V., a Viedoc user and data manager.

Verified proof points:

• Study scale: 8,000+ studies across 75+ countries
• Build speed: Average 10 weeks; self-service builds live in as little as a day
• Compliance: FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, Japan APPI; ISO 27001 and SOC 2 certified
• Japan post-market surveillance: Native PMDA-aligned module
• Support: 24/7 support; rated 4.5/5 on G2
• Pricing: Unlimited user seats, transparent study-based licensing
  
  
  

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC, the electronic data capture system at the core of the Medidata Platform, connecting study, data, and patient experience tools including eConsent, eCOA, RTSM, and imaging. Rave EDC uses AI-assisted configuration to reduce setup time and supports mid-study amendments without downtime, and the 2025 ISR Benchmarking Report, based on independent sponsor evaluations, named it the most preferred EDC. For early-phase and device work specifically, Medidata offers Rave Lite, a streamlined tier built for Phase I, Phase IV, and medical device post-market studies, using a pre-configured, pre-validated approach. Rave EDC is used across pharmaceutical, biotechnology, and medical device companies for trials spanning first-in-human through post-market observational and registry studies. Medidata is a Dassault Systèmes company.

3. Veeva EDC

Veeva offers Veeva EDC as part of the Veeva Clinical Platform, which unifies EDC with CTMS, eTMF, study start-up, and RTSM on a single cloud environment. The platform is used to design case report forms without custom programming, collects patient form data, local labs, and DICOM images, and includes targeted source data verification and protocol deviation tracking during study execution, and protocol amendments run without database downtime. Veeva maintains a dedicated MedTech vertical, with device and diagnostics customers that include several orthopedic and surgical device manufacturers running studies on the platform, alongside cardiovascular and diagnostics companies. Veeva EDC has powered more than 1,000 study starts since its release, and the broader Veeva Clinical Platform is used by more than 100 MedTech customers.

4. Castor EDC

Castor EDC is a clinical data platform combining electronic data capture, ePRO, and eConsent in one validated environment, used by device, diagnostics, and IVD teams across cardiovascular, orthopedics and MSK, surgical and interventional, and neurology studies. The platform supports first-in-human, pivotal, and post-market clinical follow-up (PMCF) studies under EU MDR, and offers AI-assisted chart review through Castor Catalyst, with every extraction reviewed by a human before it enters the study record. Low-complexity studies can launch in 3 to 4 weeks, and ePRO scheduling automates the 1, 3, and 5-year follow-up intervals common in device studies. Castor is validated against 21 CFR Part 11, GDPR, and ISO 27001, and supports GCP-aligned studies under ISO 14155. More than 890 medical device studies have run on the platform to date.

5. Medrio

Medrio provides a no-code CDMS/EDC platform alongside eCOA/ePRO, eConsent, CTMS, eTMF, and RTSM, built for MedTech, diagnostic, and digital health study teams. Sponsors and CROs configure and adapt studies without a programmer, and the platform pairs fast, code-free builds with built-in monitoring and reporting workflows covering data collection through database lock. Medrio spans nearly every milestone of the device trial process, from pre-enrollment through submission, and offers dedicated clinical trial data services for teams that want study build and data management support alongside the software. The platform complies with FDA 21 CFR Part 11, ICH GCP, HIPAA, and GDPR, and is ISO 27001 certified. Medrio has supported clinical research for more than 20 years and reports a 98% customer retention rate among its MedTech and device clients.

6. Oracle Clinical One Data Collection

Oracle offers Clinical One Data Collection, the electronic data capture component of its broader Clinical One platform, which also includes randomization and trial supply management. The system uses an AI-enabled Clinical Connector to transfer data directly from electronic health records into the EDC, reducing manual site entry, and integrates with Oracle Safety One Argus for adverse event reporting using the ICH E2B(R3) standard. Site-level document management lets sites upload subject-level files, such as scanned lab results, alongside structured data. Oracle Life Sciences' customer base includes device trial sponsors, and the platform runs on Oracle Cloud Infrastructure for global scalability. Oracle Life Sciences has more than two decades of experience in clinical development software.

What to look for in EDC solutions for musculoskeletal and orthopedic trials

Device and protocol data model adaptability

Musculoskeletal and orthopedic studies capture data a pharma-first data model doesn't anticipate: implant serial numbers and lot tracking, procedural and surgical visit types, and imaging tied to a specific joint or region. A platform that forces these into generic adverse-event or dosing templates creates rework at every site.

Best-in-class platforms let a data manager or clinical operations lead configure these fields directly in a no-code interface, without submitting a change request to a vendor programmer. Getting this wrong shows up months in, when an amendment sits in a vendor's queue while enrollment continues.

Long-horizon patient-reported outcome follow-up

Orthopedic device outcomes, especially joint replacement and spine implants, are measured over years using validated patient-reported outcome measures at repeated intervals, not once at study close. A platform that treats ePRO as a single-timepoint survey tool wasn't built for this kind of trial, so look for automated ePRO invitations across follow-up windows like 1, 3, and 5 years, with reminders and multilingual delivery built in.

Post-market and post-approval regulatory pathway support

A CE-marked device's post-market clinical follow-up clock starts immediately, and Japan's post-market surveillance requirements bring their own data structures under PMDA. Platforms without native support for these pathways force sponsors into manual workarounds right when audit scrutiny is highest. Look for structured registry, survey, and chart review designs built for EU MDR Article 61 and PMDA post-market requirements, rather than a generic adverse-event module repurposed for the job.

Lean-team self-sufficiency

Device and diagnostics companies typically run clinical operations with one or two people covering data management, site training, and regulatory documentation across several studies at once. A platform that assumes a dedicated in-house programmer or a full IT department doesn't match that reality. Best-in-class platforms put study build, mid-study amendments, and reporting directly in that lean team's hands, with training that gets a new study designer productive in days.

Audit trail depth and inspection readiness

Musculoskeletal device and biologic trials face the same FDA, EMA, and PMDA scrutiny as any regulated study, and QA teams need exportable, complete audit trails ready before an inspector asks. Best-in-class platforms build validation documentation and 21 CFR Part 11 compliant audit trails into every release, rather than requiring a fresh validation project each time the platform updates.

If your program spans broader medical device studies beyond musculoskeletal and orthopedic protocols, our wider comparison of EDC for medical devices covers additional platforms and criteria.

How to choose the right EDC solution for musculoskeletal and orthopedic trials

Step 1: Define your regulatory pathway and follow-up horizon

Whether you're running a pre-market pivotal study, an EU MDR PMCF study, a Japan PMS study, or a drug or biologic trial for an inflammatory or degenerative musculoskeletal condition changes what your data model and follow-up schedule need to support. Settle this before you evaluate platforms, since it determines which features are genuinely required versus nice to have.

Step 2: Map your device or intervention-specific fields against the platform's configurability

List the fields your protocol actually needs, implant tracking, procedural visit types, imaging uploads, patient-reported outcome instruments, and test whether you can build them yourself in a demo rather than taking a vendor's word for it.

Step 3: Assess how the platform handles multi-year follow-up without added headcount

Ask specifically how ePRO scheduling, reminders, and multilingual delivery work at the 1, 3, and 5-year marks, since this is where lean teams lose the most time to manual patient chasing.

Step 4: Scrutinize what your team can do without vendor support

Ask whether your current staff, not a hypothetical future hire, can build the initial study and make a mid-study amendment themselves, and how long that actually takes in practice.

Step 5: Choose a partner sized for where your program is headed

Viedoc's EDC software is built for exactly this profile: adaptable study design, native Japan post-market surveillance, and a no-code Designer that keeps a lean device or growth-sponsor team self-sufficient as the portfolio grows. If that matches how you run musculoskeletal or orthopedic trials, you can book a demo or request a proposal to see it against your own protocol.

Frequently asked questions

What is the best EDC software for musculoskeletal and orthopedic trials?

Viedoc's EDC software is the strongest choice for musculoskeletal and orthopedic trials, with a no-code Designer for device-specific data, study builds averaging 10 weeks, and a native Japan post-market surveillance module rare among platforms sized for lean device teams. Medidata remains the default for large enterprise pharma programs with a Rave Lite tier for early-phase and post-market device studies, though its full suite carries more overhead than most device or growth-sponsor teams need. Castor EDC is a credible alternative with direct orthopedics and MSK study experience and AI-assisted post-market chart review.

What should I look for when choosing an EDC platform for orthopedic device or musculoskeletal trials?

Look for a platform that adapts to device-specific data, implant tracking, procedural visit types, and imaging, without forcing your protocol into a pharma dosing template. Confirm it automates long-horizon patient-reported outcome follow-up at intervals like 1, 3, and 5 years, since orthopedic device endpoints are typically measured for years after enrollment closes. Check that it supports your regulatory pathway, whether that's EU MDR post-market follow-up, Japan PMDA surveillance, or FDA submission requirements, and that a lean team can build and amend the study without a dedicated programmer.

How long does it take to build and deploy a study on a modern EDC platform?

Timelines vary by platform and complexity, but modern no-code platforms typically complete study builds in weeks rather than months. Viedoc's EDC software averages 10 weeks for professional-services-managed builds, with self-service setups live in as little as a day for less complex protocols. Enterprise platforms built for large regulated pharma programs generally carry longer, more programmer-dependent build cycles, part of why device and growth-sponsor teams increasingly evaluate right-sized alternatives.

Which EDC platforms support post-market surveillance for orthopedic devices?

Viedoc's post-market surveillance software is built specifically for Japan's PMDA post-market requirements, a capability uncommon among platforms sized for the SMID device market. Castor EDC and Medidata's Rave Lite tier both support post-market and PMCF study designs, and most platforms here offer registry and observational structures suited to post-approval follow-up. The right fit depends on which jurisdiction's requirements your device is subject to, since EU MDR, FDA, and PMDA each carry distinct data and documentation obligations.

How does Viedoc compare to Medidata and Veeva for orthopedic and MSK device trials?

Viedoc and Medidata serve different points on the market: Medidata's enterprise platform and vendor-programmed configuration suit large, complex programs, while Viedoc's no-code Designer and average 10-week builds fit device and growth-sponsor teams that need to move faster with a smaller footprint. Veeva EDC is strongest for organizations already standardized on the wider Veeva Clinical Platform, where its value comes from suite-wide integration rather than standalone EDC economics. Viedoc doesn't carry the same brand recognition in large Phase III RFPs, so sponsors weighing a Phase III program should factor that in alongside build speed and cost.

What compliance certifications matter most for musculoskeletal and orthopedic device trials?

At minimum, look for FDA 21 CFR Part 11 compliance, ICH GCP alignment, and ISO 27001 and SOC 2 certification. If you're running trials in the EU, EU Annex 11 and GDPR compliance are non-negotiable, and if Japan is part of your post-market plan, confirm the platform supports Japan's APPI requirements alongside a PMDA-aligned module. QA teams should also ask for pre-built validation and inspection-readiness documentation, since rebuilding a validation package for every new platform adds real time to an already lean workload.

Making the right EDC choice for musculoskeletal and orthopedic trials

The platforms compared here span enterprise suites built for large pharma portfolios to right-sized, no-code platforms aimed at lean device and growth-sponsor teams, reflecting a broader eClinical solutions market valued at more than $11 billion in 2025 and growing at roughly 14% annually. What unites them is a shift toward self-service study build, though how far that extends varies by platform.

The right fit depends on your organizational profile. A large, multi-study pharma sponsor with an established validation team may tolerate more overhead than a five-person device clinical affairs function juggling several concurrent post-market studies. US-based teams tend to weight build speed most heavily, while EU and APAC teams weight compliance depth and vendor stability more, and budget model matters too, since per-seat pricing penalizes teams that scale headcount.

Switching EDC platforms mid-portfolio carries real validation and retraining cost, so the platform you choose for your first study is often the one your team lives with for years of post-market follow-up.

Why Viedoc is the best EDC choice for musculoskeletal and orthopedic trials

For device and growth-sponsor teams running musculoskeletal or orthopedic trials, Viedoc's EDC software is built around what generic platforms miss: adaptable study design and long-horizon follow-up. An average 10-week build and a no-code Designer mean your own team configures implant tracking, procedural visits, and multi-year ePRO follow-up without a vendor programmer in the loop.

Operationally, that means unlimited user seats and transparent, study-based pricing rather than per-seat fees that penalize a growing team, a native Japan post-market surveillance module for teams working toward PMDA requirements, and 24/7 support.

The compliance record holds up to scrutiny: ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and Japan's APPI, with the Viedoc Inspection Readiness Packet available to every customer. It's a platform proven across 8,000-plus studies in 75-plus countries, built by a company running clinical research since 2003.

If you want an EDC that adapts to your device or musculoskeletal trial's data model and follows your patients for years without adding headcount, Viedoc is designed for exactly that. Book a demo or request a proposal and the team will walk through study design flexibility, post-market surveillance support, and build speed against your own protocol.